Molar Dose Optimization for Accurate Pharmacokinetic and Biodistribution Evaluation of FAP-Targeted Radiopharmaceuticals in a Mouse Syngeneic Tumor Model
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01553 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Luoxia Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 43003…. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Membrane Proteins, Gelatinases, Serine Endopeptidases. Die Arbeit nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Most studies on fibroblast activated protein (FAP)-targeted radiopharmaceuticals focus on administered radioactivity, often overlooking the impact of a molar dose on tumor-targeting and off-target accumulation. Here, we investigate the effect of molar dose on biodistribution and pharmacokinetics using [68Ga]Ga-FAPI-04 PET and systematically evaluated two FAP-targeted dimers, DOTAGA.(SA.FAPi)2 and DOTAGA.Glu.(FAPi)2, in a 4T1 syngeneic tumor model. Dynamic PET imaging confirmed a clear molar dose-dependent effect on tumor uptake, tumor-to-organ ratios, and organ pharmacokinetics with lower molar doses prolonging tumor retention. Comparative analyses across multiple molar doses revealed that DOTAGA.Glu.(FAPi)2 achieved comparable tumor uptake to DOTAGA.(SA.FAPi)2 but exhibited significantly reduced liver accumulation. An optimal molar dose range of 8-32 nmol/kg was identified, balancing maximal tumor uptake with reduced off-target exposure. At this optimized dose, [177Lu]Lu-DOTAGA.Glu.(FAPi)2 demonstrated therapeutic efficacy in 4T1 tumor-bearing mice with limited systemic toxicity. These results establish molar dose optimization as a broadly applicable strategy for accurately evaluating and comparing FAP-targeted radiopharmaceuticals and provide a methodological framework to guide future preclinical development and translational studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430030, China.
- National Center for Major Public Health Events, 1095 Jiefang Ave, Wuhan 430030, China.
- Department of Anatomy, School of Basic Medicine, Huazhong University of Science and Technology, Wuhan 430030, China.
- Cell Architecture Research Center, Huazhong University of Science and Technology, Wuhan 430030, China.
- State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease, 1095 Jiefang Ave, Wuhan 430030, China.
ORCID-Profile: Jun Zhao, Xiaohua Zhu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, L., He, S., Huang, Z., Wang, D., Zhou, J., Yang, J., Shi, Y., Cheng, Z., Cheng, S., Zou, S., Zhao, J., & Zhu, X. (2026). Molar Dose Optimization for Accurate Pharmacokinetic and Biodistribution Evaluation of FAP-Targeted Radiopharmaceuticals in a Mouse Syngeneic Tumor Model. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01553
Vancouver
Liu L, He S, Huang Z, Wang D, Zhou J, Yang J, et al. Molar Dose Optimization for Accurate Pharmacokinetic and Biodistribution Evaluation of FAP-Targeted Radiopharmaceuticals in a Mouse Syngeneic Tumor Model. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01553
BibTeX
@article{Liu2026,
author = {Liu, Luoxia and He, Shujie and Huang, Zeyuan and Wang, Dongdong and Zhou, Jianyuan and Yang, Jingfei and Shi, Yifan and Cheng, Zhaoting and Cheng, Siyuan and Zou, Sijuan and Zhao, Jun and Zhu, Xiaohua},
title = {Molar Dose Optimization for Accurate Pharmacokinetic and Biodistribution Evaluation of FAP-Targeted Radiopharmaceuticals in a Mouse Syngeneic Tumor Model},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01553}
}
EUVIMED